Introduction
============

Sex and gender issues are important to consider in a wide range of medical conditions, including the fields of cardiovascular medicine,[@b1-ijwh-10-055],[@b2-ijwh-10-055] airway diseases,[@b3-ijwh-10-055] gastroenterology and hepatology, nephrology, endocrinology, hematology, and neurology.[@b4-ijwh-10-055] Psychiatry is another area with important gender differences. Depression is, for instance, more common in females,[@b5-ijwh-10-055] and there is a need to better understand depression in males.[@b4-ijwh-10-055] However, the impact of sex and gender is often neglected in the medical field,[@b6-ijwh-10-055],[@b7-ijwh-10-055] and most guidelines do not include even well-known sex differences.[@b8-ijwh-10-055] This may have consequences in outcome and treatment effects.[@b8-ijwh-10-055]

An area where gender differences are particularly striking is pain medicine. Women have a much higher prevalence of many pain disorders, including migraine, fibromyalgia, irritable bowel syndrome, and temporomandibular joint disorders.[@b9-ijwh-10-055] Recent evidence suggests that women's higher pain sensitivity may be explained, at least in part, by neuroimmune differences.[@b10-ijwh-10-055],[@b11-ijwh-10-055] In addition to biologic differences in pain processing, for example, putative differences in neural structures[@b9-ijwh-10-055],[@b12-ijwh-10-055] or the pain modulatory effect of sex hormones,[@b9-ijwh-10-055],[@b12-ijwh-10-055],[@b13-ijwh-10-055] psychological and sociocultural mechanisms are also thought to be important.[@b12-ijwh-10-055],[@b14-ijwh-10-055] Sex and gender differences are also important pharmacologically, for example, concerning pharmacodynamics and pharmacokinetics;[@b4-ijwh-10-055] opioid pharmacology might, for instance, be influenced by sex.[@b15-ijwh-10-055]

Pain medicine has been heavily influenced by the biopsychosocial (BPS) model launched by George L Engel in a famous paper published four decades ago.[@b16-ijwh-10-055],[@b17-ijwh-10-055] In the words of Borrell-Carrio et al, the BPS model "is a way of understanding how suffering, disease, and illness are affected by multiple levels of organization, from the societal to the molecular".[@b17-ijwh-10-055] This applies very much not only to pain medicine but also arguably to gender medicine.[@b4-ijwh-10-055],[@b18-ijwh-10-055] Established semantics mirror the broadness of the area, with "sex" being a biologic descriptor whereas "gender" is a social science descriptor.[@b18-ijwh-10-055] In this paper, both terms will be used more or less interchangeably, in accordance with a "holistic" BPS way of thinking.

A potentially illuminating way of looking at gender differences in health and disease is to study differences in drug utilization. Studies have shown that females generally use medicines (not least psychotropic drugs and analgesics) more often than males,[@b19-ijwh-10-055]--[@b22-ijwh-10-055] one important exception being cardiovascular drugs.[@b23-ijwh-10-055] The aim of this pain medicine-oriented study is to describe gender differences in dispensed systemic analgesics in Sweden from 2006 to 2015. In order to relate the findings to other drugs, a "top down" approach was chosen, that is, looking first at all Anatomic Therapeutic Chemical (ATC) groups for 2015 and then narrowing down the analysis to analgesics (including age strata and time trends).

Materials and methods
=====================

Drug classification system and defined daily dose
-------------------------------------------------

The World Health Organization Collaborating Centre for drug statistics methodology in Oslo, Norway, oversees the ATC classification system for prescription drugs, as well as the related defined daily dose (DDD) measuring unit.[@b24-ijwh-10-055] DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults, and it provides a fixed unit of measurement independent of dosage form (eg, tablet strength). ATC and DDD are important tools for international drug utilization research, and the 2015 version was used.[@b22-ijwh-10-055],[@b24-ijwh-10-055]

Materials
---------

Based on the Swedish Prescribed Drug Register,[@b25-ijwh-10-055],[@b26-ijwh-10-055] the Swedish Board of Health and Welfare holds an open, searchable statistical database containing aggregated data on all dispensed prescription drugs in Swedish pharmacies since 2006. This publicly available database is structured according to the ATC classification system, and available data are as follows: 1) total number of patients dispensed at least one prescription per year; 2) yearly prevalence (ie, number of individuals being dispensed at least one prescription per year, "patients per 1,000 inhabitants"); 3) total number of dispensed prescriptions; 4) number of dispensed prescriptions per 1,000 inhabitants; 5) total amount of DDD; and 6) DDD per 1,000 inhabitants. The database is searchable according to sex, age (5-year intervals), and Swedish regions.

In this study, only individuals ≥20 years of age were studied at a national level, focusing on sex-related differences in dispensed analgesics (ATC code N02), including systemic nonsteroidal anti-inflammatory drugs (NSAIDs; ATC code M01A). Tricyclics and gabapentinoids are first-line drugs for the treatment of neuropathic pain;[@b27-ijwh-10-055] however, these drugs were not included in this study due to the impossibility of differentiating pain-related prescription from other indications.

Statistical analysis
--------------------

To analyze these aggregated, whole-population data with nationwide coverage, descriptive statistics was used (IBM SPPS version 23 and Excel 2013). Based on the information available in the open drug statistical database of the Swedish Board of Health and Welfare, mean DDD per treated patient/year and mean number of prescriptions per treated patient/year were also calculated when appropriate.

Ethics
------

Data in this study were retrieved from a database that contains publicly available, aggregated, nationwide, whole-population information provided by the Swedish authorities. Hence, retrieving informed consent was neither possible nor necessary.

Results
=======

Yearly prevalence for all ATC codes in 2015
-------------------------------------------

The yearly prevalence for all ATC codes at the second level in Sweden 2015 is summarized in [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php?f=142052.pdf), [Table S1](https://www.dovepress.com/get_supplementary_file.php?f=142052.pdf). The yearly prevalence (patients per 1,000 inhabitants) was higher in females in 72 out of 84 ATC codes. Anti-inflammatory products (M01) and analgesics (N02) were among the most prevalent ATC codes, and both had a female/male ratio \>1 for yearly prevalence: anti-inflammatory products (M01) had a yearly prevalence of 147 in females and 115 in males, and the corresponding figures for analgesics (N02) were 241 and 154, respectively. As can be seen in [Table S1](https://www.dovepress.com/get_supplementary_file.php?f=142052.pdf), the yearly prevalence of psycholeptics (N05) and psycho-analeptics (N06) was also among the highest, with female/male ratio \>1. Given the extensive psychiatric comorbidity in chronic pain conditions (including insomnia), it was decided to include these two groups when looking at the next level in the ATC hierarchy.

Analgesics (including NSAIDs), psycholeptics, and psychoanaleptics in 2015
--------------------------------------------------------------------------

Looking at the next level in the ATC hierarchy, 10 subgroups were studied further. These are depicted in [Figure 1](#f1-ijwh-10-055){ref-type="fig"}; the female/male ratios of yearly prevalence in 2015 were (in falling order from the highest to the lowest) as follows: 3.65 for antimigraine drugs (N02C)1.87 for antidepressants (N06A)1.79 for anxiolytics (N05B)1.73 for hypnotics and sedatives (N05C)1.66 for paracetamol (N02BE01)1.52 for anti-dementia drugs (N06D)1.34 for opioids (N02A)1.28 for NSAIDs (M01A)1.19 for antipsychotics (N05A)0.93 for psychostimulants (N06B).

Hence, women had higher yearly prevalence for 9 out of 10 subgroups. With the exception of antimigraine drugs, the female/male ratios were higher for antidepressants, anxiolytics, and hypnotics and sedatives than for analgesics.

Analgesics, including NSAIDs
----------------------------

Analgesics (N02), including NSAIDs (M01A), were studied further for 2015. Only drugs with a yearly prevalence of at least 0.1% (men and women counted together) were included. The results are summarized in [Table 1](#t1-ijwh-10-055){ref-type="table"}.

When comparing the yearly prevalence (patients per 1,000 inhabitants) with the mean dose per treated patient (DDD/patient/year), the following were found: For paracetamol (N02BE01), the female/male ratio for yearly prevalence was 1.66, whereas the female/male ratio for DDD/patient/year was 1.18 (based on data pre sented in [Table 1](#t1-ijwh-10-055){ref-type="table"}).For opioids as a group (N02A), the yearly prevalence in females was 113.6 and in males was 85.1 (N02A group data are not shown in [Table 1](#t1-ijwh-10-055){ref-type="table"}), and the female/male ratio for yearly prevalence was, therefore, 1.34. The female/male ratio for DDD/patient/year for the different opioids listed in [Table 1](#t1-ijwh-10-055){ref-type="table"} ranged from 0.82 to 1.12. Hence, more females than males were prescribed opioids, but the mean dose per patient and year was not consistently higher for females.For NSAIDs as a group (M01A), the yearly prevalence was 146.5 in females and 115.4 in males, and the female/male ratio for yearly prevalence was, therefore, 1.28. The female/male ratio for DDD/patient/year for the different NSAIDs listed in [Table 1](#t1-ijwh-10-055){ref-type="table"} ranged from 0.88 to 1.21. Hence, as for opioids, more females than males were prescribed NSAIDs, but the mean dose per patient and year was not consistently higher for females.For 5HT1 agonists/triptans as a group (N02CC), the yearly prevalence was 21.1 in females and 5.6 in males, and the female/male ratio for yearly prevalence was 3.75. The female/male ratio for DDD/patient/year for the most common triptans listed in [Table 1](#t1-ijwh-10-055){ref-type="table"} ranged from 0.92 to 0.95. Hence, more females than males were prescribed triptans, but the mean dose per patient and year was slightly lower in females.

Next, the age distribution of yearly prevalence in 2015 was studied for males and females. For opioids (N02A; [Figure 2A](#f2-ijwh-10-055){ref-type="fig"}) and paracetamol (N02BE01; [Figure 2B](#f2-ijwh-10-055){ref-type="fig"}), the yearly prevalence for both males and females increased with age, with the highest prevalence recorded in the highest age group (\>85 years of age). In contrast, for 5HT1 agonists/triptans (N02CC), the yearly prevalence in both males and females peaked at 50--54 years of age ([Figure 2C](#f2-ijwh-10-055){ref-type="fig"}). For NSAIDs (M01A), the age distribution was similar to 5HT1 agonists/triptans (N02CC) for both men and women ([Figure 2D](#f2-ijwh-10-055){ref-type="fig"}). For all drug classes depicted in [Figure 2](#f2-ijwh-10-055){ref-type="fig"}, the female/male ratios were \>1 for all age groups (lines in [Figure 2A--D](#f2-ijwh-10-055){ref-type="fig"}).

Finally, time trends for yearly prevalence during 2006--2015 were investigated for males and females ([Figure 3](#f3-ijwh-10-055){ref-type="fig"}). The yearly prevalence for opioids (N02A) was stable over time, with perhaps a slight diminution of gender differences toward the end of the period ([Figure 3A](#f3-ijwh-10-055){ref-type="fig"}). Notably, the yearly prevalence of NSAIDs (M01A) diminished for both males and females during 2006--2015, whereas it increased for paracetamol (N02BE01; [Figure 3C and D](#f3-ijwh-10-055){ref-type="fig"}). For paracetamol (N02BE01), this was paralleled by a DDD increase of 38% for males and 33% in females (21--29 and 42--56 DDD/1,000 inhabitants/day, respectively). For NSAIDs (M01A), changes in yearly prevalence were paralleled by a DDD decrease of 18% for males and 26% in females (34--28 and 54--40 DDD/1,000 inhabitants/day, respectively). Comparing 2006 with 2015, the percentage changes in yearly prevalence in different age groups are depicted in [Figure 4A](#f4-ijwh-10-055){ref-type="fig"} (paracetamol) and [Figure 4B](#f4-ijwh-10-055){ref-type="fig"} (NSAIDs). The group in which paracetamol (N02BE01) dispensations changed most during the decade was in young women (the yearly prevalence increased by two-thirds, [Figure 4A](#f4-ijwh-10-055){ref-type="fig"}); however, in absolute terms, the greatest change occurred in older patients (patients \>75 years, data not shown; for the yearly prevalence of paracetamol by age group, [Figure 2B](#f2-ijwh-10-055){ref-type="fig"}). For NSAIDs (M01A), the greatest change in dispensations occurred in the older age groups, irrespective of sex; the absolute change of yearly prevalence between 2006 and 2015 was also greatest in the older age groups (similar pattern to [Figure 4B](#f4-ijwh-10-055){ref-type="fig"}).

Discussion
==========

The major findings of this study were as follows: Gender differences in drug utilization are pervasive in Sweden.Nine out of 10 subgroups of analgesics/psycholeptics/psychoanaleptics had a female/male ratio \>1 for yearly prevalence in 2015.Analgesics, including NSAIDs, were investigated closer, revealing a higher female use of drugs in all age groups in 2015 and sustained gender differences over time (2006--2015).Gender differences were particularly striking for triptans.The yearly prevalence of opioids was stable over time.During 2006--2015, the yearly prevalence of paracetamol increased, whereas that of NSAIDs decreased; these changes were most noticeable in young females for paracetamol and in older patients (irrespective of sex) for NSAIDs.

Study limitations
-----------------

The limitations of yearly prevalence and DDD as pharmacoepidemiological measures have to be pointed out. Yearly prevalence is a very crude way of measuring drug consumption, as it only reports how many patients per 1,000 inhabitants were dispensed at least one prescription of a particular drug each year. As a particular patient can get different drugs within a given ATC class, yearly prevalence measures cannot be manually added or subtracted. The limitations of yearly prevalence can partially be mitigated by reporting 1) the number of prescriptions per 1,000 inhabitants/year, 2) the number of DDD per 1,000 inhabitants, and 3) by calculating the mean DDD/patient/year and the mean number of prescriptions/patient/year. These measures are, however, still very crude, and their aggregated nature should be emphasized (ie, this study did not have access to data on an individual level). The limitation of DDD for opioids must also be stressed, as the DDD of different opioids does not take equianalgesic doses into consideration.[@b28-ijwh-10-055] Finally, it has to be underlined that this study measured dispensed medicines, not the actual drug intake. Therefore, the study does not, strictly speaking, pertain to drug utilization or consumption. The concept of adherence[@b29-ijwh-10-055] is a reminder of the fact that prescription, dispensation, and actual use should not be seen as equivalent.

All these limitations notwithstanding, this study arguably presents valuable information pertaining to gender-based differences in drug utilization in the entire Swedish population. Many of the 2015 findings of this study are congruent with results from a previous cross-sectional study from Loikas et al who analyzed data from the Swedish Prescribed Drug Register for 2010.[@b30-ijwh-10-055] However, in contrast to Loikas et al, data presented in [Table S1](https://www.dovepress.com/get_supplementary_file.php?f=142052.pdf) are not age adjusted and they do not refer to the entire population, but only to individuals \>20 years of age. In the following sections, and in agreement with the aim of the study, only analgesics will be discussed.

Analgesics and the morbidity--mortality paradox
-----------------------------------------------

In 2014, women in Sweden had a life expectancy of 84.1 years, which was almost 4 years longer than men.[@b31-ijwh-10-055] This fact, combined with the findings of this study, illustrates the so-called morbidity and mortality paradox: men are more likely to die earlier than women, but epidemiological data show that women have greater self-reported and provider-reported morbidity.[@b32-ijwh-10-055] The data presented in this paper are congruent with women having a greater self-reported morbidity. Many different factors may underlie gender differences in drug utilization. In the following text, differences in utilization of analgesics will be discussed in more detail.

Conceptually, the following reasons can be hypothesized concerning sex-based differences in the use of analgesics. First, it is well-known that females have a higher propensity for chronic pain.[@b9-ijwh-10-055] This could be due to biologic differences in pain processing, for example, putative differences in neural structures[@b9-ijwh-10-055],[@b12-ijwh-10-055] or the modulatory effect of sex hormones.[@b9-ijwh-10-055],[@b12-ijwh-10-055],[@b13-ijwh-10-055] Recent evidence also suggests that women's higher pain sensitivity may be explained, at least in part, by neuroimmune differences.[@b10-ijwh-10-055],[@b11-ijwh-10-055] Moreover, in the context of recurrent menstrual pains and the pain of childbirth, the concept of "latent sensitization" is interesting to ponder.[@b33-ijwh-10-055],[@b34-ijwh-10-055] Gender inequalities and gender stereotypes might also lead to differences in levels of psychosocial stress, which in turn might play a role in the development of chronic pain in females compared to males. A related area is sex-related differences in stress response.[@b35-ijwh-10-055]

Second, another possible reason might be that women are said to have a higher propensity to seek medical treatment, at least in high-income countries.[@b32-ijwh-10-055] Hence, all other things being equal, women would tend to seek medical help more often than men. This has, for many years, been claimed to be a rather general phenomenon,[@b32-ijwh-10-055] but, focusing on pain, it has been shown that the evidence of greater consultation for back pain and headache among women is weak and inconsistent, especially concerning back pain.[@b36-ijwh-10-055] In another study, women contacted their doctor more often than men when experiencing headache, but there was no difference concerning back pain.[@b37-ijwh-10-055] Hence, establishing whether women have a higher propensity to seek medical care or not is a difficult matter. Human behavior is, indeed, a complex phenomenon that is influenced by many different factors, and it seems sensible not to generalize or draw strong and definite conclusions. The fact that Swedish women do, indeed, seek medical care more often than men, and that their health care cost per capita in 2004 was 17% higher than men,[@b38-ijwh-10-055] might simply be due to poorer health.

Third, one can ask if there is a higher propensity for physicians to prescribe opioids to women. Indeed, it has been shown that the prescription of drugs might be influenced by the interplay between the sex of the health care provider and patient characteristics.[@b39-ijwh-10-055] It has to be remembered that prescription is an outcome of the patient--physician relationship, and that this relationship is a complex psychological and sociological phenomenon. Opioids, triptans, paracetamol, and NSAIDs will be discussed subsequently.

Opioids
-------

The yearly prevalence of opioids (N02A) was stable over time (2006--2015), with perhaps a slight diminution for females toward the end of the period ([Figure 3A](#f3-ijwh-10-055){ref-type="fig"}). Hence, Swedish physicians do not prescribe opioids to an increasing proportion of the Swedish population. Bäckryd et al have, however, recently shown that this stable prescription pattern hides a dramatic shift in the choice of opioids (ie, "within" the N02A code): the prevalences of tramadol and dextropropoxyphene have gone down substantially (the latter has been pulled off the Swedish market), whereas the prevalences of strong opioids such as oxycodone and morphine have soared.[@b40-ijwh-10-055] Although the number of oral morphine equivalents estimated by Bäckryd et al was fairly stable in 2006--2015, the shift from "weak" opioids to "strong" opioids might be problematic from an addiction medicine point of view.[@b40-ijwh-10-055] If this is the case, the stable pattern of [Figure 3A](#f3-ijwh-10-055){ref-type="fig"} would hide an increasing risk of addiction over time for females.

Some remarks have to be made concerning codeine, methadone, and buprenorphine. Plain codeine, as opposed to its combination products (eg, with paracetamol), is listed outside the N02A opioid group, namely, as a cough suppressant in R05DA04. However, R05DA04 is not widely prescribed in Sweden, its yearly prevalence in 2015 being only 0.8 patients per 1,000 inhabitants. Another opioid that falls outside the N02A group is methadone N07BC02, which is used both in opioid dependence and in pain management. The yearly prevalence of dispensed prescriptions of methadone N07BC02 in Swedish pharmacies was low (only 0.56 patients per 1,000 inhabitants). Finally, buprenorphine is placed both in the N02A group (formulations for pain management, N02AE01) and at two places in the N07BC group (drugs used in opioid dependence); N07BC01 and N07BC51 had yearly prevalences of dispensed prescriptions of only 0.18 and 0.13 patients per 1,000 inhabitants, respectively. All in all, plain codeine, methadone, and buprenorphine for opioid dependence are not included in the results presented, but they had low yearly prevalences of dispensed prescriptions and, therefore, are not essential for "the big picture".

Triptans
--------

The utilization of triptans (N02CC) in Sweden up until 2011 has been previously described;[@b41-ijwh-10-055] the present data pertain to a more recent time frame. Sex-related differences were most pronounced for triptans, with the age and sex differences depicted in [Figure 2C](#f2-ijwh-10-055){ref-type="fig"} mirroring well-known differences in migraine prevalence between women and men.[@b42-ijwh-10-055] The prescription of triptans (expressed as yearly prevalence) has been stable in Sweden during the last decade ([Figure 3B](#f3-ijwh-10-055){ref-type="fig"}). Sumatriptan was the dominant triptan; its yearly prevalence increased during the decade (7.3--9.5 patients/1,000 inhabitants/year, men and women together, data not shown), whereas the prescription of zolmitriptan and rizatriptan (second and third choice of prescribers, respectively) diminished somewhat.

Paracetamol and NSAIDs
----------------------

Traditionally, paracetamol (N02BE01) and NSAIDs (M01A) are seen as "step 1" analgesics on the World Health Organization analgesic ladder.[@b43-ijwh-10-055] The Swedish prescription pattern 2006--2015 described herein shows a shift between these "step 1" analgesics, with the yearly prevalence of paracetamol increasing whereas that of NSAIDs decreasing ([Figure 3C and D](#f3-ijwh-10-055){ref-type="fig"}).

The data of this study pertain to what could be called the "post-Vioxx" era.[@b44-ijwh-10-055],[@b45-ijwh-10-055] Indeed, not only the use of coxibs, but also certain traditional NSAIDs lead to increased cardiovascular risks.[@b46-ijwh-10-055] Naproxen seems to be the safest NSAID from a cardiovascular perspective, but naproxen users may also be at higher risk for upper gastrointestinal bleeding compared to the users of other traditional NSAIDs.[@b46-ijwh-10-055] It is not unreasonable to hypothesize that the debate on the safety of NSAIDs in general and of coxibs in particular might have influenced the prescription practice of Swedish doctors. (In contrast, the use of NSAIDs in the USA increased between 2005 and 2010.[@b47-ijwh-10-055]) Increasing age being a well-known factor for NSAID-related side effects, it is interesting to note that changes were more prominent in older patients. Going back to the aim of the study, it is notable that these changes were similar in both men and women ([Figure 4B](#f4-ijwh-10-055){ref-type="fig"}).

Concerning paracetamol, however, changes were most prominent in young women ([Figure 4A](#f4-ijwh-10-055){ref-type="fig"}). Indeed, an additional analysis during the revision stage of this paper revealed that for women 20--24 years of age, dispensed paracetamol (N02BE01) increased from 2.6 to 4.8 DDD/1,000 inhabitants/day during the study period, that is, an increase of 85% in 10 years. Interestingly, a very recent Swedish survey has shown that adults \<26 years of age perceived less risk associated with paracetamol use compared with older participants.[@b48-ijwh-10-055] There have been concerns that the increased availability of over-the-counter (OTC) paracetamol in non-pharmacy outlets since 2009 might be associated with an observed increase in paracetamol poisoning.[@b49-ijwh-10-055] In 2015, the market was re-regulated in the sense that OTC tablets of paracetamol can no longer be sold at non-pharmacies.[@b50-ijwh-10-055] The fact that the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency has recently recommended slow-release paracetamol to be removed from the market (because of difficulties in managing overdoses with this modified-release product) is a sobering reminder of the risks associated with this drug.[@b51-ijwh-10-055] A limitation of this study is that it included only one source of paracetamol (N02BE01) and not the combination preparations with opioids (in N02A). Additional data on sales of non-prescription paracetamol (and NSAIDs) in Sweden during 2010--2016 were provided by the Network for Pharmacoepidemiology, Linköping University, Sweden ([Table S2](https://www.dovepress.com/get_supplementary_file.php?f=142052.pdf)). In contrast to the trends described for Norway and Germany,[@b52-ijwh-10-055],[@b53-ijwh-10-055] OTC sales of paracetamol have been falling since 2013 and were lower in 2016 than in 2010 ([Table S2](https://www.dovepress.com/get_supplementary_file.php?f=142052.pdf)).

Conclusion
==========

In Sweden, sex differences in drug utilization are pervasive and need to be explored further. Concerning analgesics, this study showed a higher use of drugs by females in all age groups and sustained gender differences over time (2006--2015). Gender differences were particularly striking for triptans. During the last decade, for both men and women, the use of paracetamol increased while the use of NSAIDs decreased. Gender differences in the use of analgesics probably mirror the higher prevalence of chronic pain in women.

Dr Mikael Hoffmann, head of Network for Pharmacoepidemiology, Linköping University, Sweden, provided data on non-prescription paracetamol and NSAIDs while this paper was being revised.
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![Nationwide, whole-population yearly prevalence in Sweden in 2015 (patients per 1,000 inhabitants) for 10 ATC subgroups, scatter plot of males vs females.\
**Notes:** The red "gender equality line" signifies perfect gender equality in yearly prevalence. Note that the gender equality line is by no means prescriptive or normative; it is descriptive. Corresponding ATC codes: anti-dementia drugs, N06D; antidepressants, N06A; antimigraine drugs, N02C; antipsychotics, N05A; anxiolytics, N05B; hypnotics and sedatives, N05C; NSAIDs, M01A; opioids, N02A; paracetamol, N02BE01; psychostimulants, N06B.\
**Abbreviations:** ATC, anatomical therapeutic chemical; NSAIDs, nonsteroidal anti-inflammatory drugs.](ijwh-10-055Fig1){#f1-ijwh-10-055}

![Yearly prevalence in 2015 by age group and sex for (**A**) opioids (N02A), (**B**) paracetamol (N02BE01), (**C**) 5HT1 agonists/triptans (N02CC), and (**D**) NSAIDs (M01A).\
**Abbreviation:** NSAIDs, nonsteroidal anti-inflammatory drugs.](ijwh-10-055Fig2){#f2-ijwh-10-055}

![Time trends for yearly prevalence during 2006--2015 in males and females for (**A**) opioids (N02A), (**B**) 5HT1 agonists/triptans (N02CC), (**C**) paracetamol (N02BE01), and (**D**) NSAIDs (M01A).\
**Abbreviation:** NSAIDs, nonsteroidal anti-inflammatory drugs.](ijwh-10-055Fig3){#f3-ijwh-10-055}

![Changes (%) in yearly prevalence between 2006 and 2015 by sex and age group for (**A**) paracetamol (N02BE01) and (**B**) NSAIDs (M01A).\
**Abbreviation:** NSAIDs, nonsteroidal anti-inflammatory drugs.](ijwh-10-055Fig4){#f4-ijwh-10-055}

###### 

Dispensed prescription data in Sweden 2015 for the most common analgesics, including nonsteroidal anti-inflammatory drugs

  Drug and ATC code                Patients per 1,000 inhabitants   Prescriptions per 1,000 inhabitants   DDD per 1,000 inhabitants   DDD per patient   Prescriptions per patient                                  
  -------------------------------- -------------------------------- ------------------------------------- --------------------------- ----------------- --------------------------- -------- ------- ------- ----- -----
  M01AB05 diclofenac               43.6                             43.75                                 72.43                       69.62             2,328                       2,306    53.4    52.7    1.7   1.6
  M01AB55 diclofenac, comb         2.49                             1.86                                  5.22                        3.5               290                         189      116.6   101.9   2.1   1.9
  M01AE01 ibuprofen                26.99                            15.31                                 53.47                       27.39             2,010                       1,020    74.5    66.7    2.0   1.8
  M01AE02 naproxen                 61.6                             45.9                                  97.39                       68.25             5,757                       4,027    93.5    87.8    1.6   1.5
  M01AE03 ketoprofen               8.5                              4.98                                  17.64                       10.64             1,559                       1,032    183.4   207.4   2.1   2.1
  M01AE14 dexibuprofen             2.93                             2.15                                  5.62                        3.69              208                         130      71.2    60.5    1.9   1.7
  M01AH01 celecoxib                2.74                             1.52                                  5.7                         2.97              305                         157      111.5   103.1   2.1   1.9
  M01AH05 etoricoxib               12.47                            9.26                                  24.75                       17.48             1,238                       873      99.3    94.3    2.0   1.9
  M01AX01 nabumetone               1.75                             0.92                                  4.3                         1.94              250                         108      143.2   118.0   2.5   2.1
  M01AX05 glucosamine              3.15                             1.64                                  9.46                        4.31              445                         232      141.5   141.9   3.0   2.6
  N02AA01 morphine                 12.35                            8.32                                  65.51                       35.97             400                         291      32.4    35.0    5.3   4.3
  N02AA05 oxycodone                36.47                            28.38                                 163.52                      111.45            887                         766      24.3    27.0    4.5   3.9
  N02AA55 oxycodone and naloxone   4.56                             3.94                                  13.77                       9.66              90                          72       19.8    18.4    3.0   2.4
  N02AA59 codeine, comb            47.56                            35.42                                 153.1                       99.55             3,924                       2,602    82.5    73.5    3.2   2.8
  N02AB01 ketobemidone             1.5                              0.79                                  5.64                        2.72              28                          13       19.2    17.7    3.8   3.4
  N02AB03 fentanyl                 3.69                             2.1                                   19.68                       10.11             618                         341      167.6   162.7   5.3   4.8
  N02AE01 buprenorphine            8.97                             3.6                                   35.06                       14.93             411                         201      45.9    55.9    3.9   4.2
  N02AG01 morphine and antispasm   2.86                             2.16                                  6.24                        3.39              1                           1        0.5     0.48    2.2   1.6
  N02AX02 tramadol                 24.87                            19.65                                 104.5                       78.56             2,151                       1,734    86.5    88.3    4.2   4.0
  N02BE01 paracetamol              188.13                           113.22                                847.55                      418.33            20,440                      10,473   108.7   92.5    4.5   3.7
  N02CC01 sumatriptan              14.78                            4.17                                  54.93                       15.81             1,008                       299      68.2    71.9    3.7   3.8
  N02CC03 zolmitriptan             4.7                              1.14                                  21.1                        5.06              446                         117      95.1    102.8   4.5   4.4
  N02CC04 rizatriptan              2.5                              0.56                                  9.3                         2.12              135                         32       54.0    58.7    3.7   3.8

**Abbreviations:** antispasm, antispasmodics; ATC, anatomical therapeutic chemical; comb, combinations; DDD, defined daily dose.
